{"title":"STOPP/START Version 3: An Age-Friendly Evolution.","authors":"Kristin M Zimmerman","doi":"10.4140/TCP.n.2023.355","DOIUrl":null,"url":null,"abstract":"The STOPP/START criteria for Potentially Inappropriate Prescribing in Older People were initially published in 2008. The criteria were designed to be a comprehensive list of potentially inappropriate medications and potential prescribing omissions found on European formularies that were rooted in evidence and supported by expert consensus. With the expansion of the literature on medication use and outcomes in older people over the past 15 years, the criteria have been revised twice—first in 2015 (version 2) and most recently in 2023 (version 3). In their revisions, the version 3 authors worked to prioritize higher levels of evidence, including meta-analyses and randomized controlled trials.","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"38 9","pages":"355-358"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Senior Care Pharmacist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4140/TCP.n.2023.355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The STOPP/START criteria for Potentially Inappropriate Prescribing in Older People were initially published in 2008. The criteria were designed to be a comprehensive list of potentially inappropriate medications and potential prescribing omissions found on European formularies that were rooted in evidence and supported by expert consensus. With the expansion of the literature on medication use and outcomes in older people over the past 15 years, the criteria have been revised twice—first in 2015 (version 2) and most recently in 2023 (version 3). In their revisions, the version 3 authors worked to prioritize higher levels of evidence, including meta-analyses and randomized controlled trials.